Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
What is the ticker symbol for AlloVir, Inc.? What does ALVR stand for in stocks?
ALVR is the stock ticker symbol of AlloVir, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of AlloVir, Inc. (ALVR)?
As of Wed Nov 20 2024, market cap of AlloVir, Inc. is 65.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of ALVR stock?
You can check ALVR's fair value in chart for subscribers.
Is AlloVir, Inc. a good stock to buy?
The fair value guage provides a quick view whether ALVR is over valued or under valued. Whether AlloVir, Inc. is cheap or expensive depends on the assumptions which impact AlloVir, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALVR.